Linkedin X-twitter
Search

+44 (0)20 7722 1221

[email protected]

VIEW OPPORTUNITIES

SHARE

Abbott to acquire Exact Sciences in $23bn push into cancer testing

Abbott will buy Exact Sciences for $23bn, its largest deal since 2017. The move adds Cologuard, a non-invasive colorectal cancer test used 20m times since 2014. Exact shareholders will receive $105 a share, a near 50% premium.
Read the full article.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.